905961-61-7

Basic information

• Product Name: 3-(benzyloxy)cyclopentan-1-ol
• Synonyms: 3-(benzyloxy)cyclopentan-1-ol;3-(Benzyloxy)cyclopentanol
• CAS NO: 905961-61-7
• Molecular Weight: 192.258
• Mol File: 905961-61-7.mol

Chemical Properties

• CAS DataBase Reference: 3-(benzyloxy)cyclopentan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)cyclopentan-1-ol(905961-61-7)
• EPA Substance Registry System: 3-(benzyloxy)cyclopentan-1-ol(905961-61-7)

Safety Data

• Hazardous Substances Data: 905961-61-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-(benzyloxy)cyclopentan-1-ol is used as a key intermediate in organic synthesis for the preparation of various other organic compounds. Its unique structure allows for the creation of a wide range of chemical entities, making it a valuable asset in the development of new molecules with potential applications across different industries.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 3-(benzyloxy)cyclopentan-1-ol is utilized as a starting material or building block for the synthesis of drug candidates. Its functional groups and structural features enable the design and development of novel therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Chemical and Biological Research:
3-(benzyloxy)cyclopentan-1-ol is employed as a research tool in chemical and biological sciences. Its unique structure and properties make it an ideal candidate for studying various chemical reactions, mechanisms, and biological processes. Researchers can leverage 3-(benzyloxy)cyclopentan-1-ol to gain insights into the fundamental aspects of chemistry and biology, ultimately contributing to the advancement of scientific knowledge.

Upstream product

• 16326-97-9 1,3-dihydroxycyclopentane 
• 100-39-0 benzyl bromide 
• 82353-76-2 3-(benzyloxy)-6-oxabicyclo[3.1.0]hexane 
• 14320-38-8 cyclopent-3-enol 
• 37005-79-1 [(cyclopent-3-en-1-yloxy)methyl]benzene 
• 59995-47-0 4-Hydroxycyclopent-2-enone 
• 98-00-0 (2-furyl)methyl alcohol 
• 100-44-7 benzyl chloride 

Downstream Products

• 1313520-56-7 C₁₇H₂₅NO₃ 
• 905961-63-9 3-(benzyloxy)cyclopentyl methanesulfonate 
• 1062064-35-0 3-(benzyloxy)-1-methylcyclopentanol 
• 139914-48-0 3-(benzyloxy)cyclopentan-1-one 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Calcium dependent protein kinase 1 (CDPK1) is an essential Ser/Thr kinase that controls invasion and egress by the protozoan parasite Toxoplasma gondii. The Gly gatekeeper of CDPK1 makes it exquisitely sensitive to inhibition by small molecule 1H-pyrazolo

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

INHIBITORS OF PHOSPHODIESTERASE TYPE-IV

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

The preparation of optically active 2-cyclopenten-1,4-diol derivatives from furfuryl alcohol

The preparation and enzymatic resolution of several cis-mono-4-O-protected-2-cyclopenten-1,4-diols are described. The process starts with inexpensive furfuryl alcohol and lends itself to the preparation of multigram quantities of various protected, optically active 2-cyclopenten-1,4-diol derivatives. Stereoselective reduction of 4-O-protected-2-cyclopentenone to the cis-mono-O-protected-2-cyclopenten-1,4-diol using LiAlH4/LiI or Red-Al/NaI is described. Subsequent pancreatin-promoted, stereoselective acylation was conducted on these cis-(+/-)-mono-O-protected-cyclopenten-1,4-diols to afford the corresponding alcohols and acetates in moderate to excellent enantioselectivities.